News | February 10, 2024
Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Ayush is expanding beyond wellness to therapeutic wellness
Kilkari programme aims to offer weekly services, timely accessible, accurate and pertinent 72 audio messages through IVRS about reproductive maternal, neonatal and child health care
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
‘Sanjeevani’ aims to raise awareness and encourage conversations around the silent cancer epidemic
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Subscribe To Our Newsletter & Stay Updated
